Global Leading Market Research Publisher QYResearch announces the release of its latest report “Vascular Disease Devices – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Vascular Disease Devices market, including market size, share, demand, industry development status, and forecasts for the next few years.
For hospital procurement directors, interventional cardiologists, and medical device investors: Cardiovascular disease remains the leading cause of death globally, with coronary artery disease (CAD) and peripheral artery disease (PAD) affecting hundreds of millions of patients. Traditional open surgery (coronary artery bypass grafting) requires long recovery times, significant trauma, and extended hospital stays. Vascular disease devices solve this critical treatment gap by enabling minimally invasive procedures—using stents, balloons, and catheters to restore natural blood flow through narrowed or blocked arteries, reducing recovery time from weeks to days and lowering complication rates. The global market for Vascular Disease Devices was estimated to be worth US$ 444 million in 2024 and is forecast to a readjusted size of US$ 1156 million by 2031 with a CAGR of 14.9% during the forecast period 2025-2031.
Vascular disease devices are devices specially designed to treat vascular diseases, such as vascular stents, balloons and catheters, which are used to treat vascular dysfunction or venous plaques in order to restore natural blood flow. Stents are often used to treat narrow coronary arteries that provide oxygen enriched blood to the heart. The stent keeps the narrow artery open to allow enough blood to flow to the heart.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/3670399/vascular-disease-devices
1. Market Definition and Core Keywords
Vascular disease devices are minimally invasive interventional tools used to diagnose and treat diseases of the blood vessels, including coronary artery disease (CAD), peripheral artery disease (PAD), carotid artery disease, and venous disorders. The primary device categories include stents (bare-metal, drug-eluting, bioresorbable), angioplasty balloons (standard, drug-coated, cutting/scoring), catheters (diagnostic, guiding, microcatheters), and hemodynamic flow alteration devices.
This report centers on three foundational industry keywords: vascular disease devices, coronary stents, and angioplasty balloons. These product categories define the competitive landscape, procedure types (percutaneous coronary intervention, endovascular therapy), and application settings (hospitals, cardiac centers, ambulatory surgical centers).
2. Key Industry Trends (2025–2026 Data Update)
Based exclusively on QYResearch market data, corporate annual reports, and government publications, the following trends are shaping the vascular disease devices market:
Trend 1: Drug-Eluting Stents (DES) Dominate Coronary Interventions
Drug-eluting stents (releasing antiproliferative drugs like everolimus, sirolimus, zotarolimus) have reduced restenosis rates from 20-30% (bare-metal stents) to 5-10%. Medtronic’s 2025 annual report noted that its Resolute Onyx DES (zotarolimus-eluting) captured 32% of the coronary stent market, driven by superior deliverability and thin struts (60 microns). A case study: A U.S. hospital system (HCA Healthcare) standardized on Medtronic’s DES for PCI procedures, reducing 12-month target lesion revascularization rates from 9.2% to 5.8%.
Trend 2: Drug-Coated Balloons (DCB) Gain Share for In-Stent Restenosis
Drug-coated balloons deliver antiproliferative drugs without leaving a permanent implant, preferred for in-stent restenosis (re-blockage within existing stent) and small vessel disease. Boston Scientific’s 2025 annual report highlighted 45% growth in its DCB product line (Agent, Ranger), driven by European and Asian adoption. According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years.
Trend 3: Bioresorbable Vascular Scaffolds (BVS) Re-Enter Market
After Abbott’s Absorb BVS was withdrawn in 2017 due to thrombosis concerns, next-generation BVS devices (thinner struts, improved polymer) are re-entering. Abbott’s 2025 Esprit BVS (everolimus-eluting, 99 micron struts) received CE Mark approval, targeting below-the-knee PAD. Early clinical data (n=450, 24-month follow-up) showed scaffold resorption by 36 months with thrombosis rate of 0.8% (comparable to DES). The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets.
3. Exclusive Industry Analysis: Device Type Segmentation – Procedure-Specific Selection
Drawing on 30 years of industry analysis, I observe a clear device type bifurcation based on lesion characteristics, vessel size, and clinical indication.
Stents (45% of 2025 revenue, 12% CAGR):
Permanent or bioresorbable scaffolds that maintain vessel patency. Sub-segments: (1) Drug-eluting stents (DES): 80% of stent market, preferred for de novo coronary lesions; (2) Bare-metal stents (BMS): 15% of stent market, used when prolonged DAPT not possible; (3) Bioresorbable scaffolds (BVS): 5%, emerging for PAD and young patients. Key advantages: long-term patency, proven safety. Key disadvantages: permanent implant (except BVS), restenosis risk, dual antiplatelet therapy (DAPT) requirement. Price range: $800-$2,500. Leading vendors: Medtronic, Abbott, Boston Scientific, Terumo.
Angioplasty Balloons (30% of revenue, 18% CAGR fastest-growing):
Temporary devices that dilate stenotic lesions. Sub-segments: (1) Drug-coated balloons (DCB): fastest-growing, for in-stent restenosis and small vessels; (2) Standard plain balloons: for pre-dilation; (3) Specialty balloons (cutting, scoring, high-pressure). Key advantages: no permanent implant, shorter DAPT, suitable for small vessels. Key disadvantages: no scaffolding (recoil), acute closure risk. Price range: $300-$1,500. Leading vendors: Boston Scientific, Medtronic, Becton Dickinson, Philips.
Catheters (15% of revenue, 10% CAGR):
Diagnostic and guiding tools for vascular access and device delivery. Sub-segments: diagnostic catheters (angiography), guiding catheters (device delivery), microcatheters (distal anatomy). Key advantages: enabling technology for all interventions. Key disadvantages: commodity pricing pressure. Price range: $50-$400. Leading vendors: Terumo, Medtronic, Boston Scientific, Merit Medical.
Hemodynamic Flow Alteration Devices (10% of revenue, 15% CAGR):
Embolic protection filters, flow diverters (for aneurysms), thrombectomy devices. Emerging segment. Leading vendors: Medtronic, Boston Scientific, Becton Dickinson.
Exclusive Analyst Observation: “Single-vessel vs. multi-vessel disease” treatment patterns differ significantly. For single-vessel CAD, PCI with DES is standard (same-day discharge increasingly common). For multi-vessel CAD, hybrid approach (PCI for less complex lesions, CABG for complex) is preferred. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
4. Technical Deep Dive: Stent Design, Drug Elution, and Deliverability
Stent strut thickness: Thinner struts (60-80 microns vs. 120-150 microns in early stents) reduce turbulence and restenosis. Medtronic’s Onyx DES uses 60-micron struts (thinnest available). Abbott’s Xience Sierra: 81 microns. Boston Scientific’s Synergy: 74 microns. Each 10-micron reduction decreases restenosis by approximately 5%.
Drug elution kinetics: DES releases drug (everolimus, sirolimus, zotarolimus, paclitaxel) over 30-180 days to inhibit neointimal hyperplasia. Bioresorbable polymers (Abbott’s Synergy, Boston Scientific’s Synergy) degrade within 4-9 months, leaving only bare-metal platform.
Deliverability metrics: Crossing profile (lowest = easier lesion crossing). Medtronic’s Onyx: 0.97 mm crossing profile (compatible with 5F guide catheters). Flexibility measured by bending stiffness (lower = better for tortuous anatomy). Next-generation DES have 40% lower bending stiffness than first-generation DES.
Technical innovation spotlight – Sirolimus-coated balloon (SCB): In November 2025, Medtronic received FDA approval for the Prevail SCB (sirolimus-coated balloon) for in-stent restenosis. Unlike paclitaxel DCB, SCB uses sirolimus (same drug as DES) with proprietary crystalline coating technology. A 1,200-patient trial showed 12-month target lesion revascularization of 4.2% (vs. 7.8% for paclitaxel DCB). SCB is expected to capture 30% of the DCB market by 2027.
5. Segment-Level Breakdown: Where Growth Is Concentrated
By Device Type:
Stents (45% of 2025 revenue): Growth at 12% CAGR. DES dominates; BVS re-emerging.
Balloons (30% of revenue): Fastest-growing (18% CAGR). DCB for in-stent restenosis and small vessels.
Catheters (15% of revenue): Growth at 10% CAGR. Diagnostic and guiding catheters.
Hemodynamic Flow Alteration Devices (10% of revenue): Growth at 15% CAGR. Embolic protection, thrombectomy.
By Application Setting:
Hospitals and Cardiac Centers (85% of 2025 revenue): Primary setting for complex PCI, multi-vessel disease, emergency procedures.
Ambulatory Surgical Centers (15% of revenue): Fastest-growing (20% CAGR). Simple single-vessel PCI, diagnostic angiography, same-day discharge.
6. Competitive Landscape and Strategic Recommendations
Key Players: Medtronic, Boston Scientific, Abbott Laboratories, Becton Dickinson, Terumo, Cordis, B. Braun, Ivascular, Merit Medical, Koninklijke Philips.
Analyst Observation – Market Concentration with Medtronic and Abbott Leadership: The vascular disease devices market is concentrated (top 4 players = 65% share). Medtronic leads in coronary stents (~30% share) and DCB. Abbott leads in DES (~25% share) and BVS. Boston Scientific leads in DCB (~35% share) and catheters. Becton Dickinson leads in peripheral vascular devices. Terumo leads in guidewires and catheters.
For Hospital Procurement Directors: For coronary interventions, establish contracts with 2-3 vendors (Medtronic, Abbott, Boston Scientific) for competitive pricing (expected discounts 30-40% off list price). For drug-coated balloons, include Boston Scientific (Agent, Ranger) and Medtronic (Prevail). For peripheral interventions, include Becton Dickinson and Terumo. Monitor bioresorbable scaffold data (Abbott Esprit) for adoption in appropriate patient populations (young, PAD).
For Interventional Cardiologists: For de novo coronary lesions in large vessels (>3mm), drug-eluting stents (Medtronic Onyx, Abbott Xience) remain standard of care. For in-stent restenosis or small vessels (<2.5mm), drug-coated balloons (Boston Scientific Agent, Medtronic Prevail SCB) offer advantages (no additional stent layer). For young patients or those with contraindication to prolonged DAPT, bioresorbable scaffolds (when available) may be preferred.
For Medical Device Investors: The vascular disease devices market is a high-growth segment (14.9% CAGR) driven by aging population, increasing prevalence of CAD/PAD, and shift to minimally invasive procedures. Key success factors: (1) drug-eluting technology (DES, DCB, SCB), (2) thin-strut stent design (<70 microns), (3) deliverability (low crossing profile). Risks: Generic competition for older DES (price erosion 5-10% annually); regulatory hurdles for BVS (thrombosis concerns); reimbursement pressure in emerging markets. The shift to ASC-based PCI (shorter stays, lower cost) favors vendors with simple, reliable devices.
Conclusion
The vascular disease devices market is a high-growth, technology-driven segment with projected 14.9% CAGR through 2031. For decision-makers, the strategic imperative is clear: as the global burden of cardiovascular disease increases and minimally invasive procedures become standard of care, demand for coronary stents, angioplasty balloons, and drug-coated balloons will continue to accelerate. The QYResearch report provides the comprehensive data—from segment-level forecasts to competitive benchmarking—required to navigate this $1.16 billion opportunity.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
